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1. Introduction 
Neurotrophins are a family of growth factors that are polypeptide in structure and are 
necessary for the development and maintenance of the vertebrate nervous system. The first 
member of this family, nerve growth factor (NGF) was discovered in 1952 by an Italian 
group of scientists led by Rita Levi-Montalcini. She received a Nobel Prize in 1987 for her 
team’s discovery. A few decades after the discovery of NGF, brain-derived neurotrophin 
factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), and neurotrophin-5 (NT-5) 
were discovered, followed by neurotrophin-6 (NT-6) and neurotrophin-7 (NT-7) [1-3].  
2. NGF Structure 
There are two forms of NGF isolated from the short arm of human chromosome 1, a high 
molecular weight 7S NGF and a low molecular weight 2.5S NGF. The 7S form is a complex 
with three subunits (α, β and γ) and has a molecular weight of 130-140 kDa. Two beta 
subunits, each 118 amino acids long, are linked together by disulfide bonds and are 
responsible for the biological activity of NGF. The alpha and gamma subunits are members 
of the kallikrein protein family, and while the role of the alpha subunit is unknown, the 
gamma subunit is an epidermal growth factor (EGF) binding protein and has a role in the 
functions of the beta subunit. The 2.5S form has a molecular weight of 26 kDa and is formed 
by non-covalent interactions of two different subunits. NGF is synthesized and stored 
mostly in the mouse submandibular gland for reasons still unknown despite extensive 
research [3,4].   
3. NGF receptors 
Recently, it has been demonstrated that neurotrophins have many roles. Nerve growth 
factor has two receptors, p75NTR and tyrosine kinase A (Trk A), whose signaling pathways 
can be synergic, antagonistic or independent of each other [5].  
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The p75NTR receptor is a transmembrane glycoprotein with an extracellular domain and a 
member of the TNF receptor family; it has low affinity for NGF. The p75NTR is a pan-
neurotrophin receptor and, in addition to NGF, binds to other neurotrophins, such as 
BDNF, NT-3, and NT-4/5. It induces the NFκB and c-Jun kinase transduction pathways with 
varying effects depending on the pathway. The p75 receptor has been shown to act as a co-
receptor in the presence of high affinity receptors and as an antagonist in their absence. The 
p75NTR receptor is thought to act as a mediator in the pro-apoptotic process induced by 
NGF. p75NTR increases the production of ceramides and activates gene transcription or 
programmed cell death in cells [5,6].  
Receptor protein-tyrosine kinases A, B, and C (Trk A, B, C) are specific, high-affinity 
neurotrophin receptors. Trk receptors have transmembrane, extracellular, and intracellular 
domains. The portion of the Trk receptor responsible for tyrosine kinase activity, and thus 
for signal transduction, is located in the cytosolic domain. While p75 receptors bind to all 
neurotrophins, the tyrosine kinase receptor family binds to different receptors with different 
affinities. The Trk A receptor binds with high affinity to NGF but also binds to NT-3, NT-4, 
and NT-5 with low affinity. The Trk B receptor binds to BDNF and NT-4 with high affinity 
and to NT-3 with lower affinity. In contrast, the Trk C receptor only binds to NT-3 [5,7]. The 
Trk A receptor only has high affinity for NGF, and most NGF activity takes place through 
Trk A receptors. Trk A is a 140 kDa transmembrane protein encoded by proto-oncogenes on 
chromosome 1. The binding of NGF to a Trk A receptor induces tyrosine kinase receptor 
autophosphorylation, leading to the activation of parts of signal transduction cascades. 
These cascades are mainly mitogen-activated protein kinase (MAPK)-Ras-Erk, 
phospholipase Cy1, inositol triphosphate, and SNT pathways. Mutagenesis studies of the 
Trk A receptor showed that Trk A has significant effects on the development of the nervous 
system, and loss of Trk A results in neuronal loss. The Trk A receptor also induces gene 
transduction in cells [5,7].  
4. Nerve growth factor and the nervous system 
Neurotrophins are a group of structurally and functionally similar proteins that are secreted 
by a target tissue; they play a role in the development of the nervous system and in signal 
transmission. The largest concentrations of neurotrophins are found where major 
cholinergic pathways are present, such as in the hippocampus and cerebral cortex. In 
neonatal rats, when NGF is applied intracerebroventricularly, it increases the activity of 
choline acetyltransferase in the cortex and hippocampus. In addition, 
intracerebraventricular application of anti-NGF antibodies reduces the activity of choline 
acetyltransferase [7,8].  
NGF plays a role in growth, differentiation, maintenance, regeneration, neurotransmitter 
function, neurotoxin resistance, and lesions in nerve cells [7,8]. Under normal conditions, 
neurons are largely responsible for the synthesis of NGF; however, brain damage can cause 
glial cells to produce NGF as well. The blockade of the glutamate receptors and/or 
stimulation of the GABAergic system reduces NGF mRNAs in hippocampus and NGF 
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protein in hippocampus and septum [9]. The level of NGF in the nervous system and 
cerebrospinal fluid has been found to decrease with age [10,11]. During the fetal and early 
post-natal periods, neurons are NGF-dependent; however, at later stages, they become 
NGF-sensitive. NGF levels were found to be high in blood, tissue and cerebrospinal fluid of 
patients with pathological conditions, such as hypoxia, ischemia, age-related cerebral 
atrophy, and increased intracranial pressure [7,12].   
The increase in NGF levels after cerebral injury is required for neuronal recovery. Many 
studies have shown that neurotrophic factors control cellular calcium homeostasis, regulate 
cerebral blood flow, reverse the effects of ischemia, and inhibit the formation of free radicals 
by increasing antioxidant enzyme levels. However, the underlying mechanism of the 
neuroprotective role of NGF is unknown [13, 14].  
Neurotrophic factors were used in in vivo and in vitro studies of neurodegenerative diseases. 
Many of the neurotrophic factors were only used in primate models, while some were tested 
as treatment for human neurogenerative diseases. However, none of these studies provided 
satisfactory results due to technical problems, side effects, and insufficient activities. Studies 
have argued that, because of its beneficial effects, NGF may be a new potential therapeutic 
tool for the treatment of neurodegenerative diseases, especially Alzheimer's disease [15]. In 
addition, NGF has been shown to be involved in cognitive functions, especially learning 
[16].  
5. Nerve growth factor and sepsis 
Sepsis and associated clinical manifestations are the main causes of mortality and morbidity 
in intensive care units outside coronary intensive care units [17, 18]. Despite the high 
mortality, the pathophysiology of sepsis is not completely known. However, infection with 
a microorganism is known to be the first step in the development of sepsis. In order for the 
inflammatory response to occur, the activation of endogenous mediators is also required. 
There are numerous complex endogenous mediators, including the coagulation system, 
complements, kinins, cytokines, metabolites of arachidonic acid, myocardial depressant 
factor, endorphins, histamines, lysosomal enzymes, platelet activating factors, and free 
oxygen radicals. In addition to increased inflammation, mechanisms such as anti-
inflammatory cytokine secretion, anergy, and apoptosis cause immunosuppression [18-21]. 
When interactions between NGF and the mechanisms involved in sepsis pathogenesis are 
examined, NGF is found to be associated with inflammatory events and apoptosis.  
6. NGF and inflammation 
In studies conducted before the interaction of neurotrophins with the inflammation process 
was discovered, interactions between neurotrophins and immune organs and immune cells 
were investigated. In recent decades, detailed studies on the cellular localization and tissue 
distribution of neurotrophins have been completed. These studies determined that 
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neurotrophin and its receptors are present in all lymphoid organs, including the thymus and 
bursa of Fabricius [3, 22-25]. The first immune cell shown to associate with NGF was the 
mast cell, and its close localization to the nerve cells suggests the functional interaction 
between the nervous system and the immune system. Exogenous NGF was shown to 
activate mast cells in some peripheral tissues and to increase their number, size and 
degranulation [26, 27]. In addition to mast cells, NGF receptors are expressed in T and B 
lymphocytes, monocytes, macrophages, and granulocytes. Studies have shown that NGF is 
not only synthesized in immune cells, but also interacts with them [22,24,26].  
Increased NGF serum and tissue levels were also found in patients with other inflammatory 
conditions, such as allergies, asthma, cystitis, immune diseases and cardiopulmonary 
bypass [28-33]. It was determined that, when NGF is administered systemically, the 
bronchial hyperactivity induced by histamines is increased, while bronchial hyperactivity is 
inhibited by anti-NGF application. NGF interacts with tachykinins causing the increase in 
bronchial hyperactivity [32]. Human fibroblast, airway smooth muscle, and lung epithelium 
A549 cells have the ability to synthesize NGF. Synthesis in this cells is induced by pro-
inflammatory cytokines (IL-1β, TNF-α) and inhibited by glucocorticoids [34-39]. In mouse 
models of arthritis, stimulation with IL-1β has been demonstrated to increase the synthesis 
of NGF, which results in the increase of TNF-α [40]. According to some uncertain data, NGF 
has a causal role in inflammation, most likely in pro-inflammatory processes based on the 
interaction of NGF with pro-inflammatory cytokines, such as TNF-α and IL-1β.  
On the other hand, application of NGF resulted in dramatic shrinkage or disappearance of 
lesions in chronic vasculitic ulcers and allergic encephalomyelitis, and accelerated wound 
healing, which suggested an anti-inflammatory role for NGF as well [41-44]. In studies 
which investigated NGF’s interaction with anti-inflammatory cytokines, a strong interaction 
between NGF and IL-10 was found. In inflammatory processes, changes in the levels of NGF 
and IL-10 were correlated, each up-regulating the other. The effect of IL-10 on increasing the 
secretion of NGF is dose-dependent, and the application of anti-IL-10 blocks the secretion of 
NGF [42,45-47].  
In addition to pro-inflammatory and anti-inflammatory cytokines, NGF has been noted to 
interact with Toll-like receptors (TLR), which are involved in the pathogenesis of sepsis, and 
other inflammatory mediators. In the conjunctival epithelial cells obtained from patients 
with vernal conjunctivitis, NGF has been shown to modulate the expression of TLR-4 and 
TLR-9 [48]. TLR-4 signaling in the dendritic cells may activate the p38MAPK and NFκB 
pathways and induce the expression of NGF and p75 [49]. The human leukocyte antigen-DR 
(HLA-DR), CD40, CD80, CD83, CD86, and CCR7 expression induced by LPS is thought to 
cause the secretion of IL-12p40 and pro-inflammatory cytokines, such as IL-1, IL-6, and 
TNF-α. In addition, NGF was noted to inhibit the degranulation of natural killer (NK) cells; 
however, NK cells are not the cause of NGF production [50].  
In monocyte and microglial cell cultures induced by lipopolysaccharaide (LPS), LPS was 
shown to activate mRNA expression and protein release of NGF in a dose and time-
dependent manner [51,52]. The use of NFκB inhibitor pyrrolidine dithiocarbamate was also 
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shown to inhibit LPS-induced synthesis of NGF, and it was concluded that NFκB modulates 
expression of LPS-induced NGF [51]. The only study that showed the interaction between 
NGF and sepsis was conducted by Bayar et al [53]. In rats with sepsis experimentally 
induced by LPS, blood was obtained before the intervention, 2, 12, 24 and 72 hours after LPS 
injection, and serum NGF levels were measured using the Emax Immunoassay method. 
Twenty-four hours after LPS injection, NGF levels were significantly higher in sepsis-
induced rats compared to the control group. It was observed that anti-NGF administered in 
the early period, one hour before induction of sepsis, reduced the level of NGF observed 
two hours after injection. However, administration of the same dose of anti-NGF after sepsis 
was induced did not result in any change in the NGF levels. The dose of anti-NGF might 
have been inadequate to reduce NGF levels, as NGF synthesis increases after sepsis begins.   
The use of anti-NGF to eliminate the effects of NGF is a method employed in studies of the 
interaction between inflammation and NGF. While some studies have shown that NGF 
decreases inflammation in groups which have received anti-NGF [29,54], others have 
reported no change [55] or increased inflammation [56,57].  
In one study, application of anti-NGF decreased the early allergic reaction in an 
experimental model of asthma induced by intratracheal administration of ovalbumin [54]. In 
a second study using a respiratory syncytial virus (RSV) infection model, high levels of NGF 
and NGF receptors were observed in both young and adult rats. In the same study, the 
inflammatory effect of NGF was shown to decrease with age. When NGF was administered 
exogenously, expression of the neurokinin 1 (NK1) receptor, which is a sign of neurogenic 
inflammation, increased in the lungs, and pre-treatment with anti-NGF antibody decreased 
the expression of NK1 and, thus, alleviated the neurogenic inflammation [58]. In the rat 
model of inflammation generated by inoculation of Trisinella spiralis, the application of anti-
NGF prevented intestinal dysmotility in rats; however, it had no effect on inflammation [55].  
When latent herpes simplex virus (HSV-1) infected rabbits were administered anti-NGF 
antibodies, the anti-NGF was shown to react with ocular HSV-1 [57]. In another study, in 
which colitis was induced using trinitrobenzene sulfonic acid, and damage was assessed 
four weeks later, pre-treatment with anti-NGF and anti-NT-3 increased the intensity of 
inflammation 2-3 folds [56]. In acute and chronic experimental colitis models, 
neuropeptides, such as substance P and CGRP, serve a protective function and are regulated 
by NGF; when neurotrophins are experimentally and selectively blocked, the inflammation 
is significantly increased [56]. Present studies suggest that NGF has more anti-inflammatory 
effects than inflammatory. In a study investigating the interaction between sepsis and anti-
NGF, anti-NGF was applied and its effect on apoptosis was evaluated during both the early 
period, when no manifestations of sepsis are present, and the late period, when 
manifestations of sepsis are established [53].  
Studies involving NGF and anti-NGF have reported that NGF has both pro-inflammatory 
and anti-inflammatory effects. The difference might be a result of using different models of 
inflammation, applying different NGF and anti-NGF doses, and/or using different 
administration techniques. However, at the 2002 NGF meeting, it was reported that NGF 
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and Trk A weaken immune response primarily through inhibition; in other words, they 
mainly have immunosuppressant effects. Researchers argue that NGF is a potent and 
complier neuroimmunomodulator that secretes, and is secreted by, inflammatory mediators, 
and that, NGF’s proinflammatory or anti-inflammatory role can change depending on the 
type and stage of inflammation [59].  
7. NGF and apoptosis 
The term apoptosis was used for the first time in 1972 by Kerr, Wyllie, and Curie and means 
the falling of leaves from a tree in Greek. Apoptosis is the genetically controlled 
programmed cell death mechanism used by organisms to harmlessly dispose of damaged or 
unnecessary cells. Numerous physiological, adaptive, and pathological events may occur 
after apoptosis in the organism [60,61].  
Cell proliferation and cell death are balanced in tissues to provide continuity of tissue 
volume. In a 1992 study by Buchman et al., apoptosis was triggered in an experimental 
sepsis model induced by LPS [62]. In a postmortem study by Hotchkiss et al., cases that died 
from sepsis demonstrated that apoptosis occurred particularly in lymphocytes and intestinal 
epithelial cells. Although neutrophil apoptosis is known to be delayed overall during sepsis, 
a recent clinical study showed that neutrophil apoptosis increased in the earlier periods of 
sepsis. This phenomenon was explained as a mechanism to compensate for the 
inflammatory response [63]. Another study suggested that, among the immunosuppression 
mechanisms observed in sepsis, lymphocyte apoptosis is one of the most important and is a 
primary response, rather than a compensatory response [64].  
The interaction between nerve growth factor and apoptosis was first suggested in 1952 by 
Rita Levi Montalcini. She demonstrated that, during the development of sympathetic and 
sensory neurons, NGF levels were half those of normal neurons. The increase in NGF-
sensitive neurons, due to exogenous NGF application, and in neuronal death, due to anti-
NGF administration, supported her data. At the same time, NGF had an effect on regulating 
cell death in the bursa of Fabricius of chickens and in human memory B lymphocytes [65-
67]. Autocrine regulation of the cell cycle in vascular smooth muscle cells was attributed to 
NGF. The presence of NGF was detected in aortic endothelial cells. It was determined that 
NGF levels increased with pro-inflammatory cytokine IL-1ß, and after anti-NGF application, 
the cell count during S and G2/M phases and the ratio of hypodiploid cells were both 
increased [68]. In yet another study, the application of anti-NGF antibodies resulted in a 5-
fold increase in the hypodiploid DNA of LPS-activated monocyte/macrophage cultures 
compared to the control group. Morphological changes, such as round-shaped dense 
chromatin and DNA fragmentation, were also observed in apoptotic cells [52]. It was 
determined that Trk A activity inhibited cell development in PC 12 pheochromocytoma and 
neuroblastoma cells, and high expression of Trk A was correlated with neuroblastoma 
prognosis [69,70]. In a recent study, NGF was shown to inhibit the induction of cyclins, as 
well as, cyclin interaction with corresponding cyclin-dependent kinases, thus, preventing 
progression through the G1 phase of the cell cycle [71]. Cell death induced in trigeminal 
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ganglions by tunicamycin, another drug that stops the cell cycle at the G1 phase, is 
suppressed by NGF in mouse embryos [72].  
In a study of normal and NGF transgenic mice that underwent middle cerebral artery 
occlusion (MCAO), investigators evaluated infarct volume and antioxidant enzyme activity 
in the tissue that caused the occlusion. They observed higher NGF protein level increases in 
the cortical regions after ischemic damage in transgenic mice compared to the controls. In 
addition, the infarct volume and density of apoptotic cells were lower in transgenic mice. As 
a result, it was concluded that NGF had antioxidant and antiapoptotic properties [73]. Yang 
et al. reported that NGF applied after MCAO reduced apoptosis, and NGF’s neuroprotective 
effect lasted up to five hours [74]. NGF eye drops applied to a rat model of experimental 
glaucoma improved the long-term function of the optic nerve, widened the visual field, and 
inhibited apoptosis in retinal ganglion cells [75].  
Nine people volunteered for a study in which erythemas were generated with UV radiation. 
Skin biopsies were performed afterwards, and by using anti-NGF dye, the number of NGF-
positive melanocytes and keratinocytes were determined to have decreased [76]. In another 
study of rat peritoneal mast cell cultures, the effect of NGF on age-associated apoptosis was 
evaluated. It was determined that NGF prevents apoptosis in a dose-dependent manner, 
and when anti-NGF antibody is applied, NGF’s antiapoptotic effect is completely blocked 
[77]. NGF has been reported to have a protective effect on respiratory syncytial virus (RSV)-
induced apoptosis of airway epithelial cells, and therefore, it has been proposed as a new 
approach to the maintenance of respiratory tract infections [78].  
Another study evaluated neurotrophins and their receptors on diffuse large B-cell 
lymphoma (DLBCL) cells with different rituximab sensitivities. NGF secretion was induced 
by DLBLC cell exposure to rituximab, and Trk-inhibitor K252a exposure produced additive 
cytotoxic effects to rituximab [79]. Using immunohistochemical staining, bevacizumab, a 
drug used in cancer treatment, was determined to decrease the level of NGF protein, and 
thus, via NGF down-regulation, bevacizumab increases apoptosis [80]. Diabetic rats 
subjected to treadmill exercise produce increased levels of NGF to suppress apoptotic cell 
death in muscles [81].  
The hematoxylin-eosin, and other immunohistochemical stains, such as those for Bcl-2 and 
Bax, were used to stain liver, lung, and intestinal tissues in the above mentioned study 
which evaluated the effects of both early and late period anti-NGF application on apoptosis 
in experimental rat models of sepsis [53]. In this study, the increase in apoptosis was 
determined by H/E staining of all tissues from all sepsis groups. The ratio of apoptotic cells 
was more distinct in the sepsis group and in the group which received anti-NGF treatment 
in the early period. When the two groups were compared, rats from the early anti-NGF 
application group had distinctly increased levels of apoptosis in their liver and intestinal 
tissues. In addition, when early and late anti-NGF application groups were compared, the 
early anti-NGF application group exhibited a more prominent increase in apoptosis in the 
intestinal tissue compared to the late application group. When Bcl-2 staining of all tissues 
was compared, all sepsis groups were determined to have low Bcl-2 expression in the liver 
 
Sepsis – An Ongoing and Significant Challenge 112 
tissue compared to the control groups. When lung tissue was stained, all sepsis groups had 
low Bcl-2 expression compared to the control group. However, the results from the sepsis 
group without any treatment was significantly lower. In addition, when intestinal tissue 
was stained, all sepsis groups had low Bcl-2 expression compared to the control group. 
However, the results from the sepsis group without any treatment and the early NGF 
application groups were significantly lower. All groups with sepsis had increased Bax 
expression in the lung and intestinal tissues compared to the control group. In the liver 
tissue, all groups had increased Bax expression; however, the sepsis and early anti-NGF 
groups had had the highest levels of Bax expression. When the early and late NGF 
application groups were compared, Bax expression in all tissues was higher for the early 
NGF application group. The study concluded that early application of anti-NGF causes 
apoptosis at least as much as sepsis by itself; however, the application of anti-NGF after 
sepsis has been established causes less apoptosis compared to sepsis cases not treated with 
anti-NGF. The level of apoptosis was more distinct in the group with early anti-NGF 
application, which caused a prominent decrease in serum NGF levels. However, in the 
group with late application of anti-NGF and relatively stable NGF levels, less apoptosis was 
detected.  
In conclusion, no clinical study addressing the role of NGF in the pathogenesis of sepsis has 
been completed to date. However, based on the last study, the application of anti-NGF 
before the start of inflammation increases inflammation and apoptosis. The application of 
anti-NGF after the start of inflammation causes less inflammation and apoptosis compared 
to sepsis cases which do not receive any anti-NGF treatment. Based on the data 
demonstrating that anti-NGF increases inflammation and apoptosis in sepsis, it can be 
suggested that NGF has anti-inflammatory and antiapoptotic properties in sepsis cases.  
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